Yahoo Finance Top High Growth Tech Stocks to Watch in September 2024
As global markets rebound from recent sell-offs, technology stocks have led the charge, significantly outpacing their value counterparts. With the S&P 500 Index recovering from its steepest decline since March 2023 and core inflation slightly higher than expected, investors are keenly watching high-growth tech stocks that can capitalize on these dynamic market conditions. In this context, a good stock to watch in the high-growth tech sector is one that demonstrates strong performance metrics and has a positive outlook bolstered by current market sentiment.
Top 10 High Growth Tech Companies
Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
Clinuvel Pharmaceuticals | 22.41% | 27.42% | ★★★★★★ |
TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
Sarepta Therapeutics | 23.58% | 44.12% | ★★★★★★ |
Medley | 24.98% | 30.36% | ★★★★★★ |
Scandion Oncology | 40.71% | 75.34% | ★★★★★★ |
G1 Therapeutics | 27.57% | 57.75% | ★★★★★★ |
KebNi | 34.75% | 86.11% | ★★★★★★ |
Adveritas | 57.98% | 144.21% | ★★★★★★ |
Adocia | 59.08% | 63.00% | ★★★★★★ |
Travere Therapeutics | 26.68% | 68.80% | ★★★★★★ |
Click here to see the full list of 1275 stocks from our High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Trade Desk
Simply Wall St Growth Rating: ★★★★★☆
Overview: The Trade Desk, Inc. is a technology company that provides a global self-service software platform for ad buyers, with a market cap of approximately $51.80 billion.
Operations: Trade Desk generates revenue primarily from its software and programming segment, which brought in approximately $2.17 billion. The company operates both in the United States and internationally, focusing on providing a self-service platform for ad buyers.
Trade Desk has demonstrated substantial growth, with earnings rising by 95.9% over the past year and revenue forecasted to grow at 17.4% annually, outpacing the US market's 8.7%. The company repurchased 11.65 million shares for $773.08 million under its recent buyback program, indicating strong confidence in its future prospects. Their innovative solutions like Unified ID 2.0 and OpenPass are enhancing advertiser capabilities and publisher relationships, addressing key industry challenges around privacy and user engagement.
Navigate through the intricacies of Trade Desk with our comprehensive health report here.
Evaluate Trade Desk's historical performance by accessing our past performance report.
Vertex Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for treating cystic fibrosis (CF) with a market cap of $126.32 billion.
Operations: Vertex Pharmaceuticals generates revenue primarily from its pharmaceutical segment, which amounted to $10.34 billion. The company specializes in therapies for cystic fibrosis (CF).
Vertex Pharmaceuticals' focus on innovative treatments for cystic fibrosis (CF) and acute pain showcases its potential in high-growth tech. Despite a net loss of $3.59 billion in Q2 2024, the company expects product revenues to reach up to $10.85 billion this year, driven by CF therapies and new drug launches like CASGEVY®. Vertex's R&D expenses represent a significant investment in future growth, with notable advancements such as suzetrigine receiving FDA priority review. The company's strategic repurchase of 2.36 million shares for $883.81 million underscores its confidence in long-term prospects.
Zscaler
Simply Wall St Growth Rating: ★★★★★☆
Overview: Zscaler, Inc. operates as a cloud security company worldwide with a market cap of $26.19 billion.
Operations: The company generates revenue primarily through the sale of subscription services to its cloud platform and related support services, amounting to $2.17 billion. The business focuses on providing comprehensive cloud security solutions globally.
Zscaler's recent integration with CrowdStrike Falcon® for advanced threat detection and risk management highlights its innovative approach to cybersecurity. The company's R&D expenses have been substantial, amounting to $340 million in 2024, reflecting a commitment to technological advancement. Despite a net loss of $57.71 million for the year ending July 31, 2024, Zscaler's revenue grew by 34% to $2.17 billion from the previous year. Such investments and partnerships are crucial as software firms increasingly move towards SaaS models, ensuring recurring revenue streams from subscriptions.
Take a closer look at Zscaler's potential here in our health report.
Assess Zscaler's past performance with our detailed historical performance reports.
Where To Now?
Unlock more gems! Our High Growth Tech and AI Stocks screener has unearthed 1272 more companies for you to explore.Click here to unveil our expertly curated list of 1275 High Growth Tech and AI Stocks.
Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Curious About Other Options?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:TTD NasdaqGS:VRTX and NasdaqGS:ZS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
